Fezolinetant cuts hot flashes for almost 6 months
Fezolinetant 45 mg appears to be effective for up to 24 weeks in the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause in women who are considered… read more.
Fezolinetant 45 mg appears to be effective for up to 24 weeks in the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause in women who are considered… read more.
Use of non-nicotinic cytisinicline appears to help adults abstain from vaping nicotine. Researchers reported their findings on May 6, 2024 in JAMA Internal Medicine. “No medication has been… read more.
Eleven million U.S. adults use e-cigarettes to vape nicotine, and about half of them say that they want to stop, but many have trouble doing so because nicotine… read more.
AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once… read more.
On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for… read more.
Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease…. read more.
Whether it’s costs, safety risks or “pill fatigue” they’re trying to reduce, many health systems and clinics have started working on ways to encourage deprescribing of medications that… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-containing… read more.
The European Medicines Agency (EMA) has recommended the approval of twelve new products, following reviews by its key human medicines committee (CHMP). This brings to twenty-five the number… read more.
The winter flu season may be over in the northern hemisphere, but EU regulators are already looking ahead to the next outbreak in autumn 2024. Influenza viruses continuously… read more.
Despite evidence that financial conflicts of interest may influence medical practice and research and may erode patient trust in medical professionals, these relationships remain pervasive. According to a… read more.
Johnson & Johnson announced that the FDA Oncologic Drugs Advisory Committee (ODAC) recommends Carvykti (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.